Quan-T-Cell SARS-CoV-2 EUROIMMUN
NEW Quan-T-Cell SARS-CoV-2 EUROIMMUN blood test, Covid-19 memory cells. From Heparin Blood (CV2TLY from Lithium-Heparin dark blue hb tube)
Assessment of immunocompromised patients who have developed few or no antibodies.
Immune compromised patients
Immune-compromised patients are people in whom the immune system is unable or nearly unable to fight off infections or diseases. Immunosuppression can be caused by diseases, such as AIDS or lymphomas. It can also be a side effect of certain medications.
Test principle: Based on the immunological test method of an interferon gamma release assay (IGRA)
This test can only take place on location Mönchengladbach or on a project basis with courier. Or blood sample in the afternoon and then send by medical mail.
SARS-CoV-2 is transmitted primarily by respiratory droplets and aerosols containing the virus that are produced during speaking, breathing, coughing and sneezing. The incubation period of SARS-CoV-2 is three to seven, up to 14 days. The infection may be asymptomatic or produce symptoms of febrile illness with irregular lung infiltrates. Some patients, especially elderly or chronically ill patients, develop acute respiratory distress syndrome (ARDS).
Approximately 90% of SARS-CoV-2 patients develop specific antibodies up to day 10 after the onset of symptoms. COVID-19 patients also frequently produce SARS-CoV-2-reactive IFN-γ-releasing T cells.
The cytokine IFN-γ plays a central role in the defence against viruses and micro-organisms. For example, it activates macrophages and stimulates specific cytotoxic immunity. IFN-γ is produced early in the infection - before the occurrence of the anti-gene-specific adaptive immune response. How long SARS-CoV-2-specific T cells persist is not yet clear. However, recent data and experience with other human coronavirus infections show their potential persistence and ability to control viral replication and host infection, as well as their relevance to protection induced by vaccination.
Arecent US study showed that infected people are able to produce T and B cells against covid-19. That study also showed that even some uninfected people had T cells against covid-19, indicating an overlap with the response to previous coronavirus infections: called cross-reactivity. (Coronaviruses also cause SARS, MERS and, in some cases, the common cold).
Also,recent research from the Karolinska Institute in Sweden found that several covid-19 patients with mild to no symptoms had produced T cells against the virus. This was the case even in patients who had no detectable levels of antibodies against the virus. More importantly, the researchers also found evidence of T-memory cells in recovering patients. This suggests that covid-19 evokes a potent response from T-memory cells, which could prevent recurrent episodes of severe covid-19
If there are no longer any antibodies to covid-19 in the body, this does not preclude the existence of T and B memory cells, which are capable of resurfacing from their dormant state to protect the body from a new infection. In other words, the antibodies that the B cells make during the initial exposure disappear over time, but the memory cells that are created as a result last much longer.
There is still a lot we don't know. The testing methods and the knowledge of the immune system with regard to covid-19 are still in their infancy.